We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,351,533 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.76 | 67.79B |
From Apr 2019 to Apr 2024
By Philip Waller
LONDON--Inhaler developer Vectura Group PLC (VEC.LN) Thursday said its merger with SkyePharma last year has increased the company's revenue as it hit a royalty target on a deal with GlaxoSmithKline PLC (GSK.LN).
Vectura said it achieved the 9 million pounds ($11.2 million) cap on low single-digit percentage royalties from net sales of Breo/Relvar Ellipta, Anoro Ellipta and Incruse Ellipta a year earlier than planned.
The group will record GBP5.4 million of the capped amount-- from the legacy Skyepharma agreement with GSK--in its 2016 revenues, representing income since June 10, the effective date of its merger with Skyepharma.
It comes on top of royalties for a separate Vectura legacy agreement with GSK, which reached a GBP13 million calendar-year cap before GSK terminated the deal.
For the financial year to Dec. 31, the group will record GBP7.3 million of royalties under the latter legacy deal.
Chief Executive James Ward-Lilley said: "The merger with Skyepharma has added to the group's growing revenue."
-Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
February 16, 2017 03:52 ET (08:52 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
